USA: The RECOVER Initiative - Long Covid research

[bicentennial]

This has been a farcical waste by every possible metric except the NIHs own bullshit ones.

Wallitt sounds zealous and preposterous, but the explanation was that Nath came to depend on him for the organising. I vaguely recall this was on the RECOVER budget. I got the creeps in view of Wallit demonstrating a lady with fibromyalgia to prove some point she did not seem aware of. It was obscure, He has some wild ideas he is accustomed to "exploring" out loud. He sticks out.

I am surprised at the large number of various operations being networked by the budget. I could do with more local news from a lot of them. There must be some ingenious, independent-minded people in there.

 

[V.R.T.]

There must be some ingenious, independent-minded people in there.

You would hope so. Maybe some of them requested biosamples!

 

[rvallee]

The RECOVER Initiative recognizes International Long COVID Awareness Day on March 15—a day established by the Long COVID community to increase visibility of the condition, share resources, and educate the public.

Are they going to do that with medical professionals and their institutions? Because no one needs to hear and do more than them. The general public doesn't have to hear more about it, it won't ever change anything until health care systems actually do something about it.

 

[ahimsa]

Update from the NIH:

RECOVER-AUTONOMIC clinical trial results shared at 2026 ACC Conference

Ivabradine, an oral medication that lowers heart rate and is used to treat people who have chronic heart failure and an elevated heart rate, does not have a significant impact on Long COVID symptoms, according to results from the clinical trial RECOVER-AUTONOMIC (Ivabradine). These findings were shared by researchers of the NIH-funded RECOVER Initiative at the American College of Cardiology (ACC) Annual Conference on March 28, 2026.

Participant surveys showed that treatment with ivabradine did not significantly improve POTS symptoms in adults with Long COVID POTS. Ivabradine did produce a significant reduction in heart rate compared to placebo, but the lower heart rate did not improve POTS symptoms. Participants who received coordinated care in addition to ivabradine did report an improvement in their symptoms compared to those who received ivabradine and usual care.

More details about these results will be shared in an upcoming journal article.

 

[forestglip]

The results of RECOVER-VITAL (large double blind trial of Paxlovid) were posted on ClinicalTrials.gov earlier this month: https://clinicaltrials.gov/study/NCT05965726?tab=results

It looks like the results show that the Paxlovid group did not significantly improve in any outcomes.